These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34389928)

  • 1. Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.
    Donners AAMT; Rademaker CMA; Bevers LAH; Huitema ADR; Schutgens REG; Egberts TCG; Fischer K
    Clin Pharmacokinet; 2021 Nov; 60(11):1395-1406. PubMed ID: 34389928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A.
    Retout S; Schmitt C; Petry C; Mercier F; Frey N
    Clin Pharmacokinet; 2020 Dec; 59(12):1611-1625. PubMed ID: 32504271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
    Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
    Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
    Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
    Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low immunogenicity of emicizumab in persons with haemophilia A.
    Schmitt C; Emrich T; Chebon S; Fernandez E; Petry C; Yoneyama K; Kiialainen A; Howard M; Niggli M; Paz-Priel I; Chang T
    Haemophilia; 2021 Nov; 27(6):984-992. PubMed ID: 34480814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
    Jonsson F; Schmitt C; Petry C; Mercier F; Frey N; Retout S
    Clin Pharmacokinet; 2021 Jul; 60(7):931-941. PubMed ID: 33709296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
    Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
    Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
    Donners A; van der Zwet K; Egberts ACG; Fijnvandraat K; Mathôt R; Kruis I; Cnossen MH; Schutgens R; Urbanus RT; Fischer K
    BMJ Open; 2023 Jun; 13(6):e072363. PubMed ID: 37369395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
    Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J
    Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
    Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
    J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
    Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
    Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.